The use of embolic signal detection in multicenter trials to evaluate antiplatelet efficacy: signal analysis and quality control mechanisms in the CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial by Dittrich, R. et al.
 
 
 
 
 
 
 
Dittrich, R., Ritter, M.A., Kaps, M., Siebler, M., Lees, K.R., Larrue, V., 
Nabavi, D.G., Ringelstein, E.B., Markus, H.S. and Droste, 
D.W. (2006) The use of embolic signal detection in multicenter trials to 
evaluate antiplatelet efficacy: signal analysis and quality control 
mechanisms in the CARESS (Clopidogrel and Aspirin for Reduction of 
Emboli in Symptomatic carotid Stenosis) trial. Stroke, 37 (4). pp. 1065-
1069. ISSN 0039-2499 
 
http://eprints.gla.ac.uk/21021/ 
 
Deposited on: 23 January 2012 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Larrue, Darius G. Nabavi, E. Bernd Ringelstein, Hugh S. Markus and Dirk W. Droste
Ralf Dittrich, Martin A. Ritter, Manfred Kaps, Mario Siebler, Kennedy Lees, Vincent
carotid Stenosis) Trial
CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic
Antiplatelet Efficacy : Signal Analysis and Quality Control Mechanisms in the 
The Use of Embolic Signal Detection in Multicenter Trials to Evaluate
ISSN: 1524-4628 
Copyright © 2006 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online
Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
doi: 10.1161/01.STR.0000209331.39894.3d
2006, 37:1065-1069: originally published online March 2, 2006Stroke 
 http://stroke.ahajournals.org/content/37/4/1065
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/reprints
Reprints: Information about reprints can be found online at 
  
 journalpermissions@lww.com
410-528-8550. E-mail: 
Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://stroke.ahajournals.org//subscriptions/
Subscriptions: Information about subscribing to Stroke is online at 
 at GLASGOW UNIV LIB on January 23, 2012http://stroke.ahajournals.org/Downloaded from 
The Use of Embolic Signal Detection in Multicenter Trials
to Evaluate Antiplatelet Efficacy
Signal Analysis and Quality Control Mechanisms in the CARESS
(Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic
carotid Stenosis) Trial
Ralf Dittrich, MD; Martin A. Ritter, MD; Manfred Kaps, MD; Mario Siebler, MD;
Kennedy Lees, FRCP; Vincent Larrue, MD; Darius G. Nabavi, MD; E. Bernd Ringelstein, MD;
Hugh S. Markus, FRCP; Dirk W. Droste, MD
Background and Purpose—The CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid
Stenosis) trial proved the effectiveness of the combination of clopidogrel and aspirin compared with aspirin alone in
reducing presence and number of microembolic signals (MES) in patients with recently symptomatic carotid stenosis.
The present study aimed at installing primary and secondary quality control measures in CARESS because MES
evaluation relies on subjective judgment by human experts.
Methods—As primary quality control, centers participating in CARESS evaluated a reference digital audio tape (DAT)
before the study containing both MES and artifacts. Interobserver agreement of classifying signals as MES was
expressed as proportions of specific agreement of positive ratings (psvalues). For all DATs included in CARESS
(n300), online number of MES and off-line number of MES read by the central reader were compared using
correlation coefficients. As secondary control, a sample of 16 of 300 DATs was cross-validated by another independent
reader (post-trial validator).
Results—For the reference tape, the cumulative psvalue was 0.894 based on 12 of 14 observers. Two observers with very
different results improved after a training procedure. Agreement between post-trial validator and central reader was
ps0.805, indicating very good agreement. Correlation between online evaluation and off-line evaluation of DATs
was very good overall (cumulative 0.84; P0.001).
Conclusion—Multicenter studies using MES as outcome parameter are feasible. However, primary and secondary quality
control procedures are important. (Stroke. 2006;37:1065-1069.)
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Clinically silent cerebral microembolic signals (MES) canfrequently be detected by transcranial Doppler (TCD)
sonography in patients with symptomatic carotid stenosis.1–5
Several small studies have shown that MES predict recurrent
stroke or transient ischemic attack (TIA) and stroke alone in
patients with symptomatic carotid stenosis.5–8 MES-positive
patients with symptomatic carotid stenosis therefore define a
subset of high-risk patients for stroke recurrence. In this
group, MES offer an attractive surrogate marker to evaluate
antiplatelet efficacy. The CARESS (Clopidogrel and Aspirin
for Reduction of Emboli in Symptomatic carotid Stenosis)
trial demonstrated a superior efficacy of clopidogrel plus
aspirin compared with aspirin alone in reducing the presence
and the number of MES after 1 week of treatment.9 Interob-
server agreement in the identification of MES has been
shown to be high within centers and between very experi-
enced centers. However, disagreement can occur, particularly
for MES with small intensity increases.10,11 The standard of
evaluation of MES is still the off-line evaluation of a recorded
investigation by a human expert.12 Although there have been
efforts to develop intelligent software capable of automati-
cally classifying events as MES or artifacts, it is still felt that
the technique is premature.12–14 For this reason, as for most
multicenter trials involving human experts’ judgment (eg, neu-
Received August 30, 2005; final revision received November 28, 2005; accepted December 14, 2005.
From the Department of Neurology (R.D., M.A.R., D.G.N., E.B.R., D.W.D.), University Hospital of Mu¨nster, Germany; Department of Neurology (M.K.),
University Hospital of Giessen, Germany; Department of Neurology (M.S.), University Hospital of Du¨sseldorf, Germany; Division of Cardiovascular and
Medical Sciences (K.L.), University of Glasgow, United Kingdom; Department of Neurology (V.L.), University of Toulouse, France; Centre for Clinical
Neuroscience (H.S.M.), St. George’s University of London, United Kingdom; and Department of Neurology (D.W.D.), Centre Hospitalier de Luxembourg.
The first 2 authors contributed equally to this study.
Correspondence to Martin A. Ritter, MD, Department of Neurology, University of Mu¨nster, Albert-Schweitzer-Straße 33, 48129 Mu¨nster, Germany.
E-mail ritterm@uni-muenster.de
© 2006 American Heart Association, Inc.
Stroke is available at http://www.strokeaha.org DOI: 10.1161/01.STR.0000209331.39894.3d
1065
 at GLASGOW UNIV LIB on January 23, 2012http://stroke.ahajournals.org/Downloaded from 
roimaging), signal analysis during CARESS was performed in a
single reference center by an observer blinded to clinical and
patient identity details. However, to the study required individual
centers to screen for the presence, or absence, of MES.
The aim of the present study was to implement primary and
secondary quality control procedures for the evaluation of
MES. Primary quality control mechanisms before patient
recruitment were designed to ensure consistency in criteria
used to detect MES across centers. Secondary mechanisms
were designed to ensure reproducibility of the off-line anal-
ysis performed by the central reader.
Methods
Primary Quality Control: Interobserver
Agreement for a Reference Tape
Before randomization of the first patient, agreement in interpretation
of MES between centers was determined using a reference tape. This
tape contained MES of patients with carotid artery stenosis of
varying intensities recorded in the ipsilateral middle cerebral artery
and also artifacts derived from subjects coughing or talking, tapping
the probe, and electronic interference. Recordings from patients with
additional sources of MES were not used.
All recordings had been made previously for research purposes.3,13
The Doppler signal had been recorded with an EME TCD device (TC
4040; Nicolet/EME) using a 2-MHz transducer on digital audio tape
(DAT). The machine used a 128-point fast Fourier transform (FFT)
analysis and used a graded color scale to display the intensity of the
received Doppler signal. FFT time frame overlap was 67%. A sample
volume of 4 to 5 mm in length was used, and ultrasound emission
power was set to 22% of maximum output. Copies of this tape were
sent to each center with an interest to participate in the trial. The
settings of the ultrasound devices in the centers were the settings that
the centers used for MES evaluation in daily routine. The following
types of ultrasound devices were used for playback in the respective
centers: DWL Multidop X4 and Nicolet/EME TC4040. Signal
processing was performed at the playback stage using FFTs, filter
settings, and window overlaps as specified in Table 1.
Published international consensus criteria for MES detection were
used by each observer.12 Although a decibel threshold has been
shown to improve agreement,10,11 no decibel threshold was used for
this study because different analysis packages on different TCD
systems measure decibel levels in different ways, making compari-
sons of measured intensities unreliable. Each observer noted the
exact time of MES occurrence in (hh:mm:ss) according to the
counter on the DAT recorder. A time window of 1 s was allowed
for allocating a MES correctly. The decibel value measured in the
reference center was used in analysis to determine whether disagree-
ment in signal evaluation was dependent on signal intensity.
In total, 14 different experienced observers from 8 different
centers were involved:1 Mu¨nster, Germany (6 investigators)2; Glas-
gow, United Kingdom (2 investigators)3–8; Bern, Switzerland; Du¨s-
seldorf, Germany; Gießen, Germany; London, United Kingdom;
Lu¨beck, Germany; and Toulouse, France (1 investigator each).
Because the classification of MES depends on the judgment of a
human observer, we classified an event as definite MES in case of
agreement of 9 different investigators on the same signal. These
events were taken as the “gold standard.” Interobserver agreement
was expressed as proportions of specific agreement for positive
ratings (ps):15 ps2MESb/2MESbMES1MES2, where MESb
indicates the number of events classified as MES by both observers;
MES1 indicates number of events classified as MES only by the first
observer but not by the second observer; and MES2 indicates number
of events classified as MES only by the second observer but not by
the first observer.
psvalues provide probabilities that if one randomly selected
observer makes a positive rating (in this case, declaring a signal to be
a MES at a defined time), another randomly selected observer will
also make a positive rating (ie, declare the same signal as MES).
With multiple observers, the proportion declares the probability in a
cumulative manner. psvalues are comparable with widely used
-statistics. However, -values are not meaningful in the case of MES
because no specific negative rating is made during MES analysis.15
Secondary Quality Control: Cross-Validation of
Off-Line Reading Results by Post-Trial Validator
Relevant Study Design
Patients were eligible for the CARESS trial if they had recently
symptomatic (with TIA or stroke within the last 3 months) carotid
stenosis 50% based on ultrasound criteria. In subjects meeting these
entry criteria, a screening TCD was performed, and subjects were
eligible for randomization if 1 MES were detected during a 1-hour
recording. The detailed study design has been reported previously.9
TABLE 1. Setup of Doppler Devices in Participating Centers
Center 1 2 3 4 5 6 7 8 9 10 11
601 201 701 703 705 702 708 1301 1305 1303 1302
Doppler
device
EME
Pioneer
EME
Pioneer
EME
Pioneer
DWL
Multidop
EME
Pioneer
DWL
Multidop
DWL
Multidop
EME
Pioneer
EME
Pioneer
EME
Pioneer
EME
Pioneer
Transducer
size
2 cm 2 cm 2 cm 1.5 cm 1 cm 1.5 cm 1.5 cm 2 cm 2 cm 2 cm 2 cm
Transmission
frequency
2 MHz 2 MHz 2 MHz 2 MHz 2 MHz 2 MHz 2 MHz 2 MHz 2 MHz 2 MHz 2 MHz
Sample
volume
5 mm 5 mm 5 mm 5 mm 5 mm 7.5 mm 5 mm 5 mm 5 mm 5 mm 5 mm
Scale setting
(above/below
baseline)
120/120
cm/s
140/140
cm/s
130/30
cm/s
200/80
cm/s
150/10
cm/s
120/10
cm/s
150/90
cm/s
70/70
cm/s
70/70
cm/s
70/70
cm/s
70/70
cm/s
High-pass
filter
258 Hz 254 Hz 106 Hz 104 Hz 254 Hz 104 Hz 104 Hz 254 Hz 106 Hz 254 Hz 254 Hz
FFT (points) 128 128 128 128 256 64 64 128 128 128 128
Software
used
TCD 2.4 TCD 2.4 TCD 2.4 TCD 8 TCD 2.4 TCD 8 TCD 8 TCD 2.4 TCD 2.4 TCD 2.4 TCD 2.4
Window
overlap
66% 72% 67% 50% 50% 50% 50% 66% 55% 67% 67%
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During CARESS, 3 recordings within 1 week were performed
on-site in the randomizing centers and were stored on DAT. DATs
were analyzed off-line in the central reader. The central reader was
blinded to patient identity and to which tape of a given patient
corresponded to which visit.
Assessment of Off-Line Reader
For secondary quality control, 16 DATs of 300 recorded for the core
study were transferred to London (the reference center for the United
Kingdom) after the central reading procedure and were evaluated in
the same fashion as in Mu¨nster by 1 experienced observer. The
second reference reader was termed “post-trial validator.”
Five tapes of the 16 were randomly selected by the central data
management center in Paris while the study was ongoing. Eleven
tapes were selected after the trial based stratified by center and MES
count. All tapes had been allocated to 1 of 5 strata and at least 1 tape was
selected from each stratum as well as 1 from each center. The strata and
the number of tapes within each stratum are given in Table 2.
Stratification ensured that no tape was selected without any MES
(ie, 142 tapes negative on both online and off-line analysis). A
selection of tapes was made with a range containing a few too many
MES. The number of MES and the exact time of their occurrence
were documented, thus enabling a signal-to-signal comparison with
the results of the central reader, and psvalues were calculated.
Correlation of Off-Line and Online
Reading Results
After the end of the CARESS trial and unblinding of the reading
results, the online findings documented by the study site investigator
were compared with the results of the central reader. A signal-to-
signal comparison was not possible because of the fact that online
reading did not record the exact time points at which MES occurred.
Intercenter agreement was therefore expressed by both numbers of
MES detected and the decision whether a tape was MES positive or
not. Correlation coefficients were calculated for each center inde-
pendently, as well as for all centers cumulatively.
Results
Primary Quality Control: Interobserver
Agreement for a Reference Tape
A total of 290 different signals on the reference tape were
classified as MES by 1 observer. Ninety-one signals were
classified as MES by 9 observers. Table 3 shows the results
separately for each individual observer.
Two observers (12 and 13) had results very different from
the remaining 12 observers. These observers detected only 25
and 27 of the 91 reference MES. A total of 145 signals were
detected by only 1 or both of these 2 observers. The perfor-
mances of these 2 observers were independent of signal inten-
sity. The other 12 observers detected 79 of the 91 reference
MES (86%). From the remaining 56 signals that were
detected by 1 of the 12 observers who performed consis-
tently, only 7 signals had intensities 5 dB as measured by
the reference center, indicating that disagreement occurred
mainly in signals with low intensity.
Excluding observers 12 and 13, the psvalue was 0.894,
signifying a 90% likelihood that if 1 of a pair of observers
declared an event as MES, the other observer also declared
the event as MES. After including investigators 12 and 13,
the overall psvalue (agreement between all observers) fell
to 0.694. The results of the centers apart from 12 and 13 were
considered excellent.
Observers 12 and 13 were therefore considered outliers
requiring retraining. Retraining was performed by 1 of the
reference centers. The observers were then re-evaluated using
a second reference tape created in an analogous way as the
first one. Two observers from the 12 observers with good
agreement on the first tape agreed on 75 MES on the second
reference tape. For this tape, ps was 0.95 for investigator 12
and 0.71 for investigator 13, showing marked improvement.
Secondary Quality Control: Cross-Validation
of the Off-Line Reading Results With the
Findings of the Post-Trial Validator
The psvalue for the 5 randomly selected tapes during the
study was 0.815. An additional 11 tapes were validated after
the study. For the 3 stratum-1 tapes judged MES negative
during the online analysis but found positive during off-line
analysis, all were found MES negative by the post-trial
validator. For the 3 stratum-2 tapes judged MES positive
during the online analysis but MES negative during the
off-line analysis, all 3 were also found MES negative by the
post-trial validator’s analysis. For the 1 tape from stratum-3
(ie, MES positive online and MES positive off-line, but with
TABLE 2. Stratification of DATs for Secondary Quality Control
Stratum Online Off-Line n No. in Stratum
1 Negative Positive 3 29
2 Positive Negative 3 35
3 Positive 1–7 MES 1 12
4 Positive 8–19 MES 1 49
5 Positive 20 MES 3 33
Column 1 gives the No. of the stratum; column 2 (online) gives the results
of the online reading; column 3 (off-line), the results of the central reader.
The results of the off-line reader were further stratified according to the No.
of MES found per tape (1–7 MES; 8–19 MES; 20 MES).
Positive indicates investigator found MES; negative, investigator did not find
MES; n, No. of tapes randomly selected for cross-validation; No. in stratum,
absolute No. of tapes within stratum.
TABLE 3. Results of Primary Control: Results From First Master Tape (reference tape)
Investigator 1 2 3 4 5 6 7 8 9 10 11 12 13 14
No. of MES 115 92 99 99 99 91 99 96 82 90 98 117 135 95
No. of events classified as MES only by this
individual observer
5 0 0 3 0 5 0 1 0 1 1 37 66 0
No. of MES/91 MES identified by 9 observers 91 88 90 85 89 81 90 89 79 83 88 25 27 89
In the first line, the No. of the respective investigator is given. In the second line, the absolute No. of events the individual investigator classified as MES is recorded.
In the third line, the No. of events recorded as MES by the individual observer, which none of the other observers recorded as MES, is given. The fourth line indicates
the No. of MES identified by the individual investigator out of the 91 MES defined as “gold standard.”
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only few MES) the post-trial validator agreed with all 6
signals of the central reader but also found 2 more signals.
There was good agreement for the 1 tape from stratum-4 (ie,
MES positive on-line, as well as MES positive off-line, with
a considerable number of MES); the post-trial validator and
central reader agreed on 7 signals, and each validator just
found 1 extra. There was also good agreement on the 3 tapes
in the high-count stratum. The overall psvalue for these 11
tapes was 0.802. The corresponding value for all 16 tapes was
ps0.805. In summary, there was very good agreement
between central reader and post-trial validator.
Correlation of Off-Line and Online
Reading Results
For 6 of 107 randomized patients, the central reading center did
not report off-line MES during baseline recording. Therefore,
these 6 patients were excluded from the per-protocol analysis to
avoid bias because only online MES-positive patients at baseline
met the entry criteria. The numbers of MES registered during
central reading versus online analysis within each tape are given
separately for each center in the Figure.
There was an excellent correlation between the online
reader and the central reader in 6 of 11 centers (0.94 for 6
out 11 centers). For 3 centers, agreement was very good in 1
(0.88), good in 1 (0.69), and borderline in 1 (0.42;
P0.057) case. For 2 centers, there was no correlation
between off-line and online analysis (0.02 and 0.13). In
both of these centers, the ultrasound technician had changed
during the trial. The correlation of all centers combined com-
pared with the central reader was excellent (0.84; P0.001).
The main source of disagreement was, as expected, low
intensity of the signals (5 dB as measured by the EME
machine used for central analysis). This was true as well for
the comparison between the online reader and the central
reader as well as for the comparison of the post-trial validator
and the central reader.
Discussion
CARESS is the first multicenter study to use MES detection
as a surrogate end point to evaluate antiplatelet efficacy. The
trial design required individual centers to screen subjects for
the presence of MES before randomization. This required
good levels of agreement in detection of MES between
centers. In this study, we demonstrated that with appropriate
quality control measures set in place prospectively, such
multicenter studies are feasible.
Similar issues apply to all studies using neuroimaging as a
surrogate end point. For the interpretation of computed tomog-
raphy (CT) or MRI scans as surrogate markers of disease,
agreement rates of 0.6 to 0.7 are considered very acceptable
if  statistics are applied.16–18 psvalues are comparable with
Correlation graphs for all centers individually and combined. The figure shows the scatter plots and resulting correlation graphs for all
participating centers individually as well as in the lower right corner the cumulative results for all centers compared with the central
reading center. In the first line of each field center number, number of tapes contributed to the study (n), resulting coefficient (), and
resulting P values are given. Each x in the graphs indicates coordinates for the pair of results of absolute MES counts in 1 tape
achieved by the online reader (y axis) and the central reader (x axis).
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 statistics.15 Therefore, our study shows that equivalent or
higher levels of agreement can be reached in MES reading
than in CT or MRI reading.
We demonstrated that an important quality control feature
is an assessment of performance before study commence-
ment. Although most observers demonstrated high levels of
agreement at this stage, 2 observers reported MES very
different from the others. The high overall level of agreement
for most observers is consistent with previous international
reproducibility studies, which have shown good agreement
among most centers except for a few outliers.10,11 In our
study, the identification of outliers before enrollment of any
patients allowed retraining of technicians in these centers,
after which performance markedly improved. Subsequent
comparison of online and off-line analysis demonstrated poor
correlation in only 2 centers, both of which had a change in
ultrasound technician during the study. This emphasizes the
importance of re-evaluating any new technicians during the
study, something that was not performed in CARESS.
Previous studies have shown high levels of interobserver
reproducibility in the detection of MES.10,11 These were
cross-sectional studies and involved a number of internation-
ally recognized and expert centers. We demonstrated similar
levels of agreement between most centers in this study. Our
study extends these findings in a number of ways. First, we
included all centers in the CARESS trial, not all of which had
such extensive experience in MES detection. Second, we
evaluated the effect of retraining less well-performing centers
and demonstrated this resulted in a marked improvement in
performance. Third, in this prospective study, we monitored
the performance of centers during the trial by comparing their
online analysis with the off-line analysis of the central
reading center. This demonstrated the need for continued
monitoring and particularly re-evaluation and, if necessary,
training if technicians performing the recordings change
during the study. This is a standard procedure in other clinical
trials using neuroimaging.16–18 This was something that was
not performed in the CARESS study.
There are a number of potential limitations in our study.
First, 290 signals were declared as MES by 1 observer, but
only 91 MES were considered as “reference MES” against
which statistical tests were performed. This seemingly high
level of disagreement in the number of MES is well explained
by the fact that the 2 outliers were responsible for 145 of 199
of the signals not considered as MES for the purpose of the
study and that only 7 of the remaining 56 signals had high
signal intensities. This demonstrates that the disagreement
occurred mainly in the low-intensity range, something that
was expected before the trial.
Therefore, not using a decibel threshold for MES could be
regarded as the second limitation. However, because of the
different equipment used, it was not possible to use a fixed
value. The lack of an intensity threshold also did allow us to
evaluate agreement across the full range of MES intensity and
demonstrated the relationship between disagreement and
intensity. A third limitation could be that not all centers used the
same ultrasound device for signal analysis. This could lead to a
systematic error for centers that use a device different from
the central reading center. However, our study does not
support this assumption because the results of the readers for
the reference tape and during the trial using DWL or EME
machines were not very different.
In summary, we have shown that it is possible to standard-
ize MES reading and that MES are a robust tool suitable as a
surrogate marker for clinical trials as long as independent
quality control mechanisms are installed.
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